Loading
Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006.
Beijing Gene Key Life Technology appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2, 2), testing GKL-006 in hepatocellular carcinoma (hcc), unresectable hepatocellular cancer, advanced pancreatic cancer, ductal adenocarcinoma of pancreas. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.
Shares the tags china, registry-only.